Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Trending on Bing
Music legend Jones dies
Diagnosed with cancer
How to vote
Holds rally in Michigan
Holds rally in Pennsylvania
South Carolina fined $250K
Euthanized in New York
Ejected for throwing punch
Israel ends agreement
Raiders fire Luke Getsy
WA mall shooting arrest
Taurid meteor showers
IA voter challenges allowed
China crew returns to Earth
DC boosts security efforts
Iranian-American detained
Hand-in ballots suit rejected
NC sees turnout record
Penalized by NASCAR
Airstrikes hit Gaza
OPEC extends output cuts
Golden Glove winners
Win New York City Marathon
Portis' home burglarized
Approves Emrosi for rosacea
Massachusetts brush fires
Tops box office again
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Stock Tumbles
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by wholesale distributors hurt sales of its diabetes drug Mounjaro and anti-obesity medicine Zepbound.
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling
Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand.
11d
on MSN
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
4d
Ozempic, Wegovy move closer to no longer being in shortage, FDA says
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
6d
on MSN
What You Need To Know Ahead of Eli Lilly's Earnings Wednesday
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
4d
on MSN
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
7h
Novo's new obesity drug, Wegovy in race to becoming top selling franchise
The Danish drugmaker’s arch-rival
Eli
Lilly
& Co. has introduced another shot ... the diabetes shot that’s often taken ...
The American Journal of Managed Care
3d
5 Essential Drugs Currently Facing Shortages
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
4d
on MSN
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
12d
Shady drugmaker used code words to sell knockoff weight-loss drug: Lawsuit
Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...
4d
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...
This Is Money on MSN
10d
Can YOU cash in on the pharma giants leading the weight loss boom?
The boom experienced by the weight loss drug market comes as little surprise when considering that almost a third of the ...
Reuters on MSN
4h
Analysis-Americans hungry for weight-loss drugs grapple with supply and insurance hurdles
(Reuters) - Americans are still eagerly seeking prescriptions for
Eli
Lilly
... its diabetes
drug
Ozempic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback